how many people are taking glp 1 drugs GLP-1 Agonists Weight Loss Market Report, 2025-2030 The GLP-1 Access Gap: Mapping
Description
Key players such as Novo Nordisk (DK), Eli Lilly (US), and Sanofi (FR) are at the forefront, each employing distinct strategies to enhance their market positions
approved for type 2 diabetes, with some formulations phased out over time
De Heer J, Rasmussen C, Coy DH, Holst JJ
For instance, in February 2024, the Ministry of Health, Canada, introduced Bill C-64 to establish universal pharmacare, covering diabetes drug such as insulin USD 900-USD 1,700/year, metformin ~USD 100/year, and adjunct therapies USD 100-USD 1,000+/year for type 1 and type 2 diabetes patients under single-payer insurance
A significant factor is often the substantial caloric restriction that accompanies treatment
The highest price respondents would accept paying skewed lower among those who used to take a GLP-1 or are thinking of taking the drug
